Stock listing

OTC:CDBKF Cloudbreak Pharma, Inc. Stock

US listing (OTC) of Cloudbreak Pharma, Inc. · home listing HKEX:2592

Follow Cloudbreak Pharma, Inc. into a list and get an email when it puts out news.

Home listing price · HKEX:2592

$1.19 HKD 0.00 (0.0%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, HKEX:2592

Past year -74.7% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$1.19 – $1.19 HKDNov 20, 2026
Market cap
$1.10B HKDAt the close on Nov 20, 2026 · price × 924.7M shares outstanding
52-week range
$0.90 – $9.58 HKDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$20,896 HKDMedian day 0 shares · 41 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026
Cloudbreak Pharma, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
HKEX:2592 · Home$1.19 HKD0.00 (0.0%)—$1.19$1.19$1.19$1.19Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · HKEX:2592 · HKD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$1.190.000.0%$1.19$1.19$1.190
$1.190.000.0%$1.19$1.19$1.190
$1.190.000.0%$1.19$1.19$1.190
$1.190.000.0%$1.19$1.19$1.190
$1.190.000.0%$1.19$1.19$1.190
$1.190.000.0%$1.19$1.19$1.190
$1.190.000.0%$1.19$1.19$1.190
$1.190.000.0%$1.19$1.19$1.190
$1.190.000.0%$1.19$1.19$1.190
$1.190.000.0%$1.19$1.19$1.190
$1.190.000.0%$1.19$1.19$1.190
$1.190.000.0%$1.19$1.19$1.190
$1.190.000.0%$1.19$1.19$1.190
$1.190.000.0%$1.19$1.19$1.190
$1.190.000.0%$1.19$1.19$1.190
$1.190.000.0%$1.19$1.19$1.190
$1.190.000.0%$1.19$1.19$1.190
$1.190.000.0%$1.19$1.19$1.190
$1.190.000.0%$1.19$1.19$1.190
$1.190.000.0%$1.19$1.19$1.190
$1.190.000.0%$1.19$1.19$1.190
$1.190.000.0%$1.19$1.19$1.190
$1.190.000.0%$1.19$1.19$1.190
$1.190.000.0%$1.19$1.19$1.190
$1.190.000.0%$1.19$1.19$1.190
$1.190.000.0%$1.19$1.19$1.190
$1.190.000.0%$1.19$1.19$1.190
$1.190.000.0%$1.19$1.19$1.190
$1.190.000.0%$1.19$1.19$1.190
$1.190.000.0%$1.19$1.19$1.190
$1.190.000.0%$1.19$1.19$1.190
$1.190.000.0%$1.19$1.19$1.190
$1.190.000.0%$1.19$1.19$1.190
$1.190.000.0%$1.19$1.19$1.190
$1.190.000.0%$1.19$1.19$1.190
$1.190.000.0%$1.19$1.19$1.190
$1.190.000.0%$1.19$1.19$1.190
$1.190.000.0%$1.19$1.19$1.190
$1.190.000.0%$1.19$1.19$1.190
$1.190.000.0%$1.19$1.19$1.190
$1.190.000.0%$1.19$1.19$1.190
$1.19+0.025+2.1%$1.165$1.21$1.16518,500
$1.165-0.02-1.7%$1.17$1.195$1.1638,500
$1.185+0.005+0.4%$1.18$1.195$1.1856,500
$1.18+0.025+2.2%$1.165$1.18$1.1693,500
$1.1550.000.0%$1.15$1.165$1.1543,000
$1.155+0.01+0.9%$1.145$1.17$1.11534,500
$1.1450.000.0%$1.14$1.145$1.1432,500
$1.145-0.01-0.9%$1.16$1.16$1.14548,000
$1.155-0.04-3.3%$1.195$1.195$1.15571,500
$1.1950.000.0%$1.195$1.23$1.18168,500
$1.195+0.035+3.0%$1.15$1.23$1.1571,000
$1.16-0.02-1.7%$1.155$1.16$1.1555,000
$1.18-0.02-1.7%$1.20$1.225$1.16128,000
$1.20+0.035+3.0%$1.145$1.21$1.145140,500
$1.165-0.005-0.4%$1.145$1.175$1.1443,000
Ticker
OTC:CDBKF
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
OTC
Currency
USD

What changed lately

Latest news

All Cloudbreak Pharma, Inc. news

Cloudbreak Pharma, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
15 in the last 12 months · 16 in all · newest Nov 13, 2026 · oldest 2025
Decks
1 deck · latest Apr 8, 2026

Where Cloudbreak Pharma, Inc. is listed

ListingExchangeCountryCurrency
HKEX:2592 撥康視雲 · Home listingHKEXHong KongHKD
OTC:CDBKF · This pageOTCUnited StatesUSD

Valuation

Price/book 2.3× against a median of 1.1×: 8th lowest of 9 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · price Nov 20, 2026

Enterprise value
$643.0M HKD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
2.3×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta
No index for this market yet

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Cloudbreak Pharma, Inc. · HKEX:2592US$140.4MUS$82.03Mn/an/an/a2.3×n/a0.0×n/a
ProQR Therapeutics N.V. · NASDAQ:PRQRUS$146.8MUS$49.73Mn/a2.2×n/a2.0×−210.7%0.2×1.73
ALX Oncology Holdings Inc. · NASDAQ:ALXOUS$146.6MUS$9.57Mn/an/an/a1.2×n/a0.1×0.68
Bicycle Therapeutics PLC · NASDAQ:BCYCUS$146.1M−US$323.8Mn/a−3.9×n/a0.3×−169.8%0.0×1.59
BridgeBio Oncology Therapeutics, Inc. · NASDAQ:BBOTUS$145.3M−US$46.23Mn/an/an/a0.5×n/a0.0×1.49
TYK Medicines, Inc. Class H · HKEX:2410US$144.9MUS$137.0Mn/an/an/a3.7×n/a0.6×n/a
Sutro Biopharma, Inc. · NASDAQ:STROUS$142.8MUS$259.6Mn/a5.8×n/an/a−344.2%n/a1.14
VISEN Pharmaceuticals · HKEX:2561US$140.7MUS$91.29Mn/a29.8×n/a1.4×n/a0.3×n/a
Protara Therapeutics, Inc. · NASDAQ:TARAUS$140.4MUS$15.77Mn/an/an/a1.0×n/a0.0×1.12
Scancell Holdings PLC · LSE:SCLPUS$140.2MUS$155.6Mn/an/an/an/an/an/an/a
Abeona Therapeutics Inc. · NASDAQ:ABEOUS$138.4MUS$15.29Mn/a0.4×n/a1.1×−160.3%0.1×1.00
Median of the othersUS$143.8MUS$32.75M2.2×1.1×−190.2%0.1×1.14

Team and board

OfficerRole
Jinsong NiFounder, Chief Executive Officer
Van DinhChief Operating Officer
Abu AbrahamChief Medical Officer
Elizabeth CapanChief Patent Officer
Greg BrooksChief Commercial Officer
Michael RoweChief Business Officer
Rong YangChief Scientific Officer

Decks

DeckKindSlidesDate
Investor Presentation (April 2026)Investor deck23 slidesApr 8, 2026

Open Decks

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022
Revenue010.0M00
Research and development66.8M37.9M27.5M15.3M
Selling, general and administrative40.9M9.49M2.62M5.42M
Operating income-107.4M-37.2M-35.8M-23.7M
Depreciation and amortization620.0K1.23M829.0K329.0K
EBITDA-106.8M-36.0M-34.9M-23.4M
Interest expense23.0K27.0K275.0K31.0K
Income before tax-67.8M-98.3M-129.4M-66.8M
Net income-67.7M-99.1M-129.4M-66.8M
Earnings per share, basic-0.08-0.12-0.15-0.08

Balance sheet

LineFY2025FY2024FY2023FY2022
Cash and equivalents40.1M34.9M52.7M15.9M
Short-term investments18.2M7.50M63.2M
Inventory110.0K0
Current assets64.3M37.5M61.5M80.1M
Total assets66.6M40.0M64.8M82.1M
Accounts payable836.0K1.76M2.10M1.23M
Current liabilities6.02M391.3M327.4M226.7M
Total liabilities6.12M391.6M327.6M227.3M
Shareholders' equity60.5M-351.5M-262.8M-145.2M
Shares outstanding844.6M838.9M838.9M838.9M

Cash flow

LineFY2025FY2024FY2023FY2022
Cash from operations-51.5M-26.5M-22.5M-20.1M
Capital spending-18.2M-155.0K-2.21M-778.0K
Free cash flow-69.7M-26.7M-24.7M-20.8M
Change in cash5.02M-17.6M36.9M-64.2M

Open Financials

Filings

Open Filings

Cap table

Built by 6ix from Cloudbreak Pharma, Inc.’s releases

Common shares
924,692,316
Fully diluted
924,692,316

Fully diluted

LineShares
Common shares924,692,316

Share count over time

CountShares
Nov 22, 2026924,692,316

Open Cap table

Shareholders

HolderSharesOf the companyAs of
Leng Bing237M27.9%Apr 1, 2026
Ni Jinsong237M27.9%Apr 1, 2026
Water Lily Consultants Inc.214M25.1%Apr 1, 2026
Bright Future Pharmaceutical Laboratories Limited95.5M11.4%Jul 3, 2025
CHAN Chak Yeung95.5M11.4%Jul 3, 2025
WONG Cheong Moon95.5M11.4%Jul 3, 2025
Kung Hung Ka97.7M10.6%Sep 3, 2026
Wealth Strategy Holding Limited97.7M10.6%Sep 3, 2026
Dinh Van Son66.4M7.8%Apr 1, 2026
vdtlcapital64.4M7.6%Apr 1, 2026
All 18 holders
HolderSharesOf the companyAs of
CDH China HF Holdings Company Limited49.6M5.9%Jul 3, 2025
CDH Griffin Holdings Company Limited49.6M5.9%Jul 3, 2025
CDH Wealth Management Company Limited49.6M5.9%Jul 3, 2025
Central Oak Company Limited49.6M5.9%Jul 3, 2025
Skketch Shine Limited49.6M5.9%Jul 3, 2025
CDH Investment Management Company Limited49.6M5.9%Jul 3, 2025
WU Shangzhi49.6M5.9%Jul 3, 2025
Yicun Holdings Limited46.9M5.6%Jul 3, 2025

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Abu AbrahamChief Medical Officer · Since at least Jun 22, 2026
Elizabeth CapanChief Patent Officer · Since at least Nov 5, 2026
Greg BrooksChief Commercial Officer · Since at least Nov 5, 2026
Jinsong NiFounder, Chief Executive Officer · Since at least May 12, 2026
Michael RoweChief Business Officer · Since at least Nov 5, 2026
Rong YangChief Scientific Officer · Since at least Nov 5, 2026
Van DinhChief Operating Officer · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about Cloudbreak Pharma, Inc.